SKIPPACK, Pa., Dec. 14 At GeoInvesting.com, we have been tracking Tianyin Pharmaceuticals (NYSE Amex: TPI) for some time now. Our largest hang up had been with the potential dilution from "in-the-money" warrants. Although the Company's fiscal June 2010 net income guidance of $11.3 million represents a 43.0% increase from the fiscal 2009 reported net income of $7.9 million, the increase in shares poses some uncertainty regarding the near term EPS growth scenario, which depends upon the share price and the Treasury method of accounting for these warrants under GAAP. (Tianyin reported 32 cents per share for its 2009 fiscal year, based on 24.8 million shares).
Having said that, on December 3, 2009 Tianyin issued fiscal 2011 net income guidance of $19.6 million, implying earnings per share figure of 50 cents, fully taxed. Combine this with an overall positive outlook, a very accomplished management team, cash available to make potential future acquisitions, and the TPI story begins to gain strength.
Biostar Pharmaceuticals (OTC Bulletin Board: BSPM) is another pharmaceutical company whose stock we own. Through our interview with management, BSPM demonstrated that it has a coherent understanding of its markets and the steps necessary to accelerate growth.
Biostar manufactures & distributes 15 nonprescription, prescription and nutraceutical products. There are 3 aspects of the Company's story that are worth considering. First, Biostar's Hepatitis flagship drug is the only one offered over the counter in Chinese drug stores.
To view more on TPI and BSPM , please visit the following link:
You agree that you shall not republish or redistribute in any medium any information on the GeoInvesting website without our express written authorization. You acknowledge that GeoInvesting is not registered as an exchange, broker-dealer or investment advisor under any federal or state securities laws, and that GeoInvesting has not provided you with any individualized investment advice or information. Nothing in the website should be construed to be an offer or sale of any security. You should consult your financial advisor before making any investment decision or engaging in any securities transaction as investing in any securities mentioned in the website may or may not be suitable to you or for your particular circumstances.
GeoInvesting Contacts: Dan David, Vice President Maj Soueidan, President Zou Soueidan, Equity Analyst Ph. 610-409-9297 Web site: http://www.geoinvesting.com/